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Introduction: We investigated whether attachment of gelatin hydrogel microsphere (GHM) sheet
impregnated with antagomir-92a on the infarcted heart promotes angiogenesis and cardiomyogenesis,
and improves cardiac function after myocardial infarction (MI) in rats.
Methods: GHM sheet impregnated with antagomir-92a, its scramble sequence antagomir-control sheet
or the sheet alone was attached on the area at risk of MI after the left anterior descending coronary artery
ligation. Bromodeoxyuridine (BrdU) was included in the sheet to trace proliferating cells.
Results: The antagomir-92a sheet signiﬁcantly increased capillary density in the infarct border zone 14
days after MI compared to the antagomir-control sheet or the sheet alone, associated with an increase in
endothelial cells incorporated with BrdU. The antagomir-92a sheet signiﬁcantly increased cardiac stem
cells incorporated with BrdU 3 days after MI in the infarct border zone. This was associated with an
increase in cardiomyocytes incorporated with BrdU 14 days after MI. Scar area was signiﬁcantly reduced
by the antagomir-92a sheet compared to the antagomir-control sheet or the sheet alone (12.8 ± 1.3 vs
25.2 ± 2.2, 24.0 ± 1.7% LV area, respectively) 14 days after MI. LV dilatation was inhibited, and LV wall
motion was improved 14 days after MI in rats with the antagomir-92a sheet compared to the antagomir-
control sheet or the sheet alone.
Conclusions: These results suggest that attachment of the GHM sheet impregnated with antagomir-92a
on the area at risk of MI enhances angiogenesis, promotes cardiomyogenesis, and ameliorates LV
function.
© 2016, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
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Since current pharmacological and interventional approaches
are limited to salvage the damaged heart after myocardial infarc-
tion (MI), cardiac regeneration therapy has emerged as an attractive
treatment option for severe MI. However, the ideal method of
cardiac regeneration therapy has not been established.
Cardiac regeneration therapy consists of cell-based or
molecular-based therapy. Each therapy possesses advantages and
disadvantages. Cell-based therapy can directly replenish the
damaged heart. However, successful cell transplantation requires
optimizing the best cell type and site for engraftment, overcoming
limitations to cell migration and tissue integration, and occasion-
ally needing to control immunologic reactivity [1]. Therapeutic
approaches for cell-based therapy involve bone marrow-derived
mononuclear cells and their subsets such as mesenchymal stem/sting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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tissue-derived MSCs, cardiac tissue-derived stem cells, and cell
combinations. Clinical trials employing these cells have demon-
strated that cellular therapy is feasible and safe, but overall clinical
efﬁcacy in patients with MI is modest [2,3]. Therefore, cell-based
therapy is still challenging and further innovations are needed to
be established as a common clinical practice.
On the other hand, molecular-based therapy has mainly focused
on therapeutic angiogenesis, because angiogenesis is a key to suc-
cess for cardiac regeneration after MI, Protein delivery or gene
transfer of angiogenic growth factors such as vascular endothelial
growth factor (VEGF) and ﬁbroblast growth factor (FGF) has
demonstrated improvement in tissue perfusion and morphological
and angiographic evidence of new vessel formation in various in-
stances of animal models [4,5]. Such reproducible and credible
successes in early animal studies have prompted clinical trials
employing angiogenic growth factors. Unfortunately, in spite of
promising early data coming from many pioneering clinical trials,
recent larger and better-designed clinical trials provided disap-
pointing results. An appreciable number of randomized controlled
trials using VEGF and FGF proteins have shown far from optimal
results [6]. Similarly, several phase I and phase II clinical trials using
angiogenic gene transfer in patients with coronary artery disease
have provided limited evidence regarding the efﬁcacy and long-
term sustainability of therapeutic effect, although generally sup-
porting the safety and tolerability of angiogenic gene transfer [7].
Such limited success of molecular-based therapy using angiogenic
gene transfer for cardiac regeneration may be attributed to the fact
that tissue repair is not a simple process. Understanding cells, the
signals that they respond to, and the keys to appropriate survival
and tissue formation are orders of magnitude more complicated
than understanding the pathways targeted by most genes. Thus, it
is anticipated that targeting any single genes is difﬁcult to confer
appreciably beneﬁcial outcomes for regeneration of the heart after
MI.
MicroRNAs (miRs) are small non-coding RNAs with short ~22
nucleotide RNA sequences that bind to complementary sequences
in the 30 UTR of multiple target mRNAs, usually resulting in their
silencing or translational repression. Each miR inhibits the function
of hundreds of target RNAs, thereby integrating and ﬁne-tuning the
network of cellular processes involved in plethora of biological
events including cardiovascular development and angiogenesis
[8,9]. The ability of single miRs to modulate multiple gene
expression makes them an attractive tool in cardiac regeneration
therapy.
The miR-17-92 cluster has been considered as a therapeutic
target for angiogenesis. The miR-17-92 cluster is composed of miR-
17, miR-18a, miR-19a/b, miR-20a, and miR-92a. It was among the
ﬁrst miRs that were linked to tumor angiogenesis [10]. Over-
expression of the entire miR-17-92 cluster in myc-induced tumors
increased angiogenesis by a paracrine mechanism [11]. Interest-
ingly, miR-92a has been found as a negative regulator of endothelial
function and angiogenesis. Bonauer et al. [12] demonstrated that
miR-92a is increased in the heart after MI, and systemic adminis-
tration of antagomir-92a augmented neovascularization and
repaired the infarcted tissue in mice. Moreover, the efﬁcacy of anti-
miR-92a therapy may not be conﬁned to angiogenesis but is also
attributed to cell-protective and anti-inﬂammatory effects [13].
Such pleiotropic salutary effects of anti-miR-92a on cardiac
regeneration have prompted the investigators to develop a delivery
system to optimally antagonize miR-92a in the post-infarction
myocardium.
A critical issue in systemic administration of pro-angiogenic
proteins or genes is unwanted angiogenesis in off-target organs
such as cancer tissues and eyes with diabetic retinopathy. Systemicadministration also requires a large quantity of drugs. Local de-
livery of pro-angiogenic agents overcomes such drawbacks. Indeed,
catheter-based delivery of locked nucleic acid-modiﬁed antisense
miR-92a was found to be more effective than systemic delivery in
protecting the pig heart after MI [13]. However, proteins, plasmids
or oligonucleotides are readily degraded or dissipated after local
delivery to the target tissue. Therefore, the therapeutic efﬁcacy of
bolus injection of antagomir-92a into the heart may be limited. To
achieve long-lasting delivery of antagomir-92a into the infarcted
myocardium, we developed a biodegradable gelatin hydrogel
microsphere (GHM) sheet that is slowly degraded and release
impregnated plasmid DNA or proteins over 14 days [14]. We
attempted to use the GHM sheet impregnated with antagomir-92a
in the rat with acute MI, because mir-92a increases on the day 1
after MI, peaked on the day 2 and then gradually decreases over 14
days [12]. Therefore, the efﬁcacy of the GHM sheet was thought to
be maximally brought out by applying it to the heart immediately
after MI. In this acute MI model, we investigated whether
controlled local delivery of antagomir-92a to the heart increases
angiogenesis, enhances cardiomyogenesis, and improves left ven-
tricular (LV) function after MI.
2. Methods
2.1. Preparation of GHM-impregnated sheet
Antagomir-92a and its scramble sequence antagomir-control
were synthesized by Greiner Bio-One (Frickenhausen, Germany)
as described previously [12]. The GHM sheet used in the present
study was prepared as described previously [15]. Brieﬂy, GHMs
were prepared by chemical cross-linking of aqueous gelatin solu-
tion with glutaraldehyde (GA). Gelatin with an isoelectric point of
5.0 was prepared as an acidic gelatin. After we mixed 2.5 mmol of
aqueous GA solution (Wako Pure Chemical Industries, Osaka, Japan)
with aqueous gelatin solution (5 wt%) preheated at 40 C, themixed
aqueous solution was cast into balance dishes and left for 12 h at
4 C to allow for chemical cross-linking of gelatin. The resulting
GHM sheets were placed in 100 mmol/L aqueous glycine solution
and then agitated at 37 C for 1 h to block the residual aldehyde
groups of unreacted GA. Cross-linked GHM sheets were thoroughly
washed with double-distilled water (DDW), freeze-dried, and
sterilized with ethylene oxide gas. GHM sheets were then trimmed
in approximately 10  10-mm squares and 0.7-mm thick. Next,
DDW containing 1 mg of antagomir-92a or antagomir-control was
added drop-wise onto freeze-dried GHM sheets under sterile
conditions and then left for 1 h to allow the GHM to be impreg-
nated. The RNA-free, empty GHM sheets were prepared by the
same method as described above.
2.2. Animal preparation
Male SpragueeDawley rats weighing 250e300 g were used in
the present study. All animals were handled in accordance with the
“Guide for the Care and Use of Laboratory Animals” prepared by the
Institute of the Care and Use of Laboratory Animal Resources, Na-
tional Research Council, and published by the National Academy
Press, revised in 1996. The study was approved by the Animal Care
Committee of Kansai Medical University (Moriguchi, Japan).
2.3. Surgical procedures
The rats were anesthetized with xylazine (5 mg/kg, s.c.) and
ketamine (100 mg/kg, i.m.), and placed on a temperature-
controlled surgical table. The trachea of rats was cannulated
with a polyethylene tube connected to a respirator (Shinano,
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100/min. The rats were then anesthetized with 1.5e2.0% iso-
ﬂurane under controlled ventilation with a respirator for the
remainder of the surgical procedure. A left thoracotomy was
performed between 4th and 5th ribs, and the pericardial sac was
removed. The left anterior descending (LAD) coronary artery was
ligated at a middle portion with 6-0 prolene sutures to produce
MI. The rat receiving sham surgery underwent the same procedure
except the suture was passed under the coronary artery and then
removed. The GHM sheet was cut into a trapezoid shape and ﬁxed
on the epicardium surrounding the area at risk of infarction with 3
sutures (Fig. 1). The chest was then closed in three layers (ribs,
muscle, and skin), and the animal was allowed to recover. Body
temperature was maintained at 37 C throughout the surgical
procedure. Buprenorphin (0.1 mg/kg i.p.) was administered after
surgery to alleviate pain.
2.4. Echocardiography
Transthoracic echocardiography was performed 1 h and 14 days
after the LAD coronary artery ligation using a SONOS-7500 echo-
cardiography system (Philips Medical Systems, Andover, MA, USA)
equipped with a 15-MHz transducer. The following parameters
were measured: 1) LV wall motion score (1 ¼ normal,
2 ¼ hypokinetic, 3 ¼ akinetic, 4 ¼ dyskinetic, and 5 ¼ aneurismal),
2) maximal LV end-diastolic diameter (LVDd), and 3) fractional
shortening (FS) calculated as [LVDd  LV end-systolic diameter
(LVDs)/LVDd]  100. Wall motion score index was evaluated as
described previously [16]. All measurements were averaged for 3
cardiac cycles and performed by an experienced operator blinded
to the treatment group.
2.5. Immunohistochemical analysis
To identify proliferating cells 100 mg/kg of bromodeoxyuridine
(BrdU) (Sigma, Tokyo, Japan) was impregnated into the GHM sheet.
Three days or 14 days after the LAD coronary artery ligation the rats
were sacriﬁced by intraperitoneal injection with overdose sodium
pentobarbital (100 mg/kg). The heart was removed quickly and cut
horizontally at the mid-LV level. The frozen sample was sectioned
at a 6 mm thickness and mounted on glass slides. The frozen sec-
tions were stained for BrdU using a sheep polyclonal primary
antibody (Meridian Life Science, Memphis, TN, USA) followed by aFig. 1. Attachment of gelatin hydrogel microsphere sheet on the area at risk of myocardial inf
B; dashed line indicates estimated area at risk of infarction after ligation of the left anterior d
at risk of myocardial infarction.cy5-conjugated secondary antibody (PerkinElmer, Waltham, MA,
USA). The slidewas then incubated with a primary antibody against
an endothelial marker CD-31 (BD Biosciences, San Jose, CA, USA), a
stem cell marker c-kit (LifeSpan BioSciences, Seattle, WA, USA), or a
cardiomyocyte marker a-actinin (Sigma, Tokyo, Japan) and stained
with a cy3-conjugated secondary antibody (PerkinElmer). DAPI
(40,6-Diamidino-2-phenylindole) was obtained from Invitrogen
(Carlsbad, CA, USA) and used for nuclear staining. The slide was
viewed with a ﬂuorescence microscope (BZ 9000, Keyence, Osaka,
Japan). For the quantitative measurement, the number of cells
stained with BrdU and CD-31, c-kit or a-actinin was counted at the
border of infarction in the mid LV free wall or the posterior LV wall
away from infarction. Eight non-overlapping random ﬁelds from 4
sections of each heart were examined. Counts of stained cells per
mm2 were obtained after superimposing a calibrated morpho-
metric grid on each digital image using Win Roof (Mitani, Fukui,
Japan).
2.6. Measurement of infarct size
Fourteen days after the LAD coronary artery ligation the heart
was cut horizontally at the mid-LV level, ﬁxed with 10% formalin,
embedded in parafﬁn, and sectioned at a 6 mm thickness. The sec-
tion was stained with Masson's trichrome, and the area at risk of
infarction and the scar area were quantiﬁed by morphometric
analysis as described previously [17].
2.7. Statistical analysis
Statistical analyses were conducted with a commercially avail-
able software package (StatView 5.0, SAS Institute Inc, Cary, NC,
USA). Differences between groups were assessed by one-way
analysis of variance (ANOVA) followed by the TukeyeKramer test.
All numerical data are expressed as the means ± SE. The differences
were considered signiﬁcant at a p value < 0.05.
3. Results
3.1. GHM sheet impregnated with antagomir-92a increases
angiogenesis
There were abundant CD-31-positive endothelial cells in the
non-infarct area (posterior LV wall) 14 days after LAD coronaryarction in rats. A; gelatin hydrogel microsphere sheet impregnated with antagomir-92a.
escending coronary artery. C; gelatin hydrogel microsphere sheet attached on the area
M. Fujita et al. / Regenerative Therapy 5 (2016) 9e1612artery ligation, but there are virtually no-endothelial cells with
positive-immunostaining for BrdU (Fig. 2A). There were only a
small number of endothelial cells with positive-immunostaining
for BrdU in the infarct border zone 14 days after MI, when the
GHM sheet without antagomir-92a was attached on the area at riskFig. 2. The effect of the gelatin hydrogel microsphere sheet impregnated with antagomir-92
endothelial cell proliferation. Red, CD-31; green, bromodeoxyuridine (BrdU); blue, DAPI. G
impregnated with antagomir-92a; Ant-Co, gelatin hydrogel microsphere sheet impregnat
indicate 20 mm. Lower panel; quantitative analysis for BrdU-positive endothelial cells. Each b
effect of the GHM sheet impregnated with antagomir-92a on capillary density. Red, CD-31. Ba
bar graph indicates mean ± SE of 5 experiments. #p < 0.05 compared to sham, *p < 0.01 cof MI. The GHM sheet impregnated with antagomir-92a provoked a
robust increase in BrdU-positive endothelial cells in the infarct
border zone. Such an increase in BrdU-positive endothelial cells
was not observed, when the GHM sheet was impregnated with
antagomir-control.a on angiogenesis. A; the effect of the GHM sheet impregnated with antagomir-92a on
HM, gelatin hydrogel microsphere sheet; Ant-92a, gelatin hydrogel microsphere sheet
ed with antagomir-control. The arrows indicate BrdU-positive endothelial cells. Bars
ar graph indicates mean ± SE of 5 experiments. *p < 0.01 compared to Ant-92a. B; the
rs indicate 20 mm. Lower panel; quantitative analysis for the number of capillaries. Each
ompared to Ant-92a.
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days after LAD coronary artery ligation, when the GHM sheet
without antagomir-92a was attached on the area at risk of MI
(Fig. 2B). The GHM sheet impregnated with antagomir-92a but not
antagomir-control highly signiﬁcantly (p < 0.01) increased capillary
density in the infarct border zone.
3.2. GHM sheet impregnated with antagomir-92a increases cardiac
stem cell proliferation
It has been demonstrated that c-kit-positive cardiac stem cells
normally reside in the heart and presumably are responsible for
replenishing the pool of cardiomyocytes and endothelial cells un-
der normal conditions [18e20]. Therefore, we investigatedwhether
c-kit-positive cardiac stem cells are accumulated in the infarcted
tissue. There were no c-kit-positive cells in the non-infarct area
(posterior LV wall) 3 days after MI (Fig. 3). There were only a small
number of c-kit-positive cells that incorporated BrdU in the infarct
border zone 3 days after MI, when the GHM sheet without
antagomir-92a was attached on the area at risk of MI. c-kit and
BrdU-positive cells were dramatically increased in the infarct
border zone 3 days after MI, when the GHM sheet impregnated
with antagomir-92a was attached on the area at risk of MI. There
was no increase in c-kit and BrdU-positive cells when the GHM
sheet impregnated with antagomir-control was attached on the
area at risk of MI.
3.3. GHM sheet impregnated with antagomir-92a increases
cardiomyogenesis
There was no cardiomyocytes that incorporated BrdU in the
non-infarct area 14 days after MI (Fig. 4). There were only a small
number of cardiomyocytes that incorporated BrdU in the infarct
border zone 14 days after MI, when the GHM sheet withoutFig. 3. The effect of the gelatin hydrogel microsphere sheet impregnated with antagomir-92
DAPI. GHM, gelatin hydrogel microsphere sheet; Ant-92a, gelatin hydrogel microsphere
impregnated with antagomir-control. The arrows indicate BrdU-positive cardiac stem cells.
cells. Each bar graph indicates mean ± SE of 5 experiments. *p < 0.01 compared to Ant-92antagomir-92awas attached on the area at risk of MI. BrdU-positive
cardiomyocytes were markedly increased by the GHM sheet
impregnated with antagomir-92a. These cardiomyocytes were
relatively smaller than mature cardiomyocytes as observed in the
non-infarct area, and the cluster of BrdU-positive cardiomyocytes
formed islands in the infarct border zone. The GHM sheet
impregnated with antagomir-control did not increase BrdU-
positive cardiomyocytes 14 days after MI, and the island of car-
diomyocytes was appreciably smaller than that observed in the
GHM sheet impregnated with antagomir-92a.
3.4. GHM sheet impregnated with antagomir-92a reduces infarct
size
There was no difference in the area at risk of infarction between
the groups 14 days after LAD coronary artery ligation (Fig. 5). When
the GHM sheet impregnated with antagomir-92a was attached on
the area at risk of MI, the scar area was highly signiﬁcantly
(p < 0.01) reduced 14 days after MI compared to the sheet alone or
the sheet impregnated with antagomir-control.
3.5. GHM sheet impregnated with antagomir-92a improves LV
function
LV wall motion score index was not different between the
groups 1 h after LAD coronary artery ligation (Fig. 6A), suggesting
equal degree of LV dysfunction at the time of MI. LV wall motion
score index was signiﬁcantly increased 14 days after LAD coronary
artery ligation in all groups. However, deterioration of LV wall
motion score index was signiﬁcantly inhibited, when the GHM
sheet impregnated with antagomir-92a but not antagomir-control
was attached on the area at risk of MI.
LVDd was not different between the groups 1 h after LAD cor-
onary artery ligation (Fig. 6B). LVDd signiﬁcantly increased 14 daysa on cardiac stem cell proliferation. Red, c-kit; green, bromodeoxyuridine (BrdU); blue,
sheet impregnated with antagomir-92a; Ant-Co, gelatin hydrogel microsphere sheet
Bars indicate 20 mm. Lower panel; quantitative analysis for BrdU-positive cardiac stem
a.
Fig. 4. The effect of the gelatin hydrogel microsphere sheet impregnated with antagomir-92a on cardiomyocyte proliferation. Red, a-actinin; green, bromodeoxyuridine (BrdU);
blue, DAPI. GHM, gelatin hydrogel microsphere sheet; Ant-92a, gelatin hydrogel microsphere sheet impregnated with antagomir-92a; Ant-Co, gelatin hydrogel microsphere sheet
impregnated with antagomir-control. The arrows indicate BrdU-positive cardiomyocytes. Bars indicate 20 mm. Lower panel; quantitative analysis for BrdU-positive cardiomyocytes.
Each bar graph indicates mean ± SE of 5 experiments. *p < 0.01 compared to Ant-92a.
Fig. 5. The effect of the gelatin hydrogel microsphere sheet impregnated with antagomir-92a on infarct size. Fibrous tissues (scars) are stained with blue and cardiac muscles are
stained with red. GHM, gelatin hydrogel microsphere sheet; Ant-92a, gelatin hydrogel microsphere sheet impregnated with antagomir-92a; Ant-Co, gelatin hydrogel microsphere
sheet impregnated with antagomir-control. Lower panel; quantitative analysis for % risk area/left ventricle (LV) and % scar area/LV. Each bar graph indicates mean ± SE of 5 ex-
periments. *p < 0.01 compared to Ant-92a.
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Fig. 6. The effect of the gelatin hydrogel microsphere sheet impregnated with antagomir-92a on left ventricular function after myocardial infarction (MI). A; wall motion score
index. Filled triangle, GHM sheet (n ¼ 5); ﬁlled circle, GHM sheet impregnated with antagomir-92a (n ¼ 5); ﬁlled square, GHM sheet impregnated with antagomir-control (n ¼ 5).
Each symbol represents mean ± SE. *p < 0.05 compared to GHM sheet impregnated with antagomir-92a. B; left ventricular end-diastolic diameter (LVDd) and C; FS; fractional
shortening. Sham, sham surgery; GHM, gelatin hydrogel microsphere sheet; Ant-92a, gelatin hydrogel microsphere sheet impregnated with antagomir-92a; Ant-Co, gelatin
hydrogel microsphere sheet impregnated with antagomir-control. Open bars; 1 h after left anterior descending (LAD) coronary artery ligation, ﬁlled bars; 14 days after LAD coronary
artery ligation. Each bar graph indicates mean ± SE of 5 experiments. #p < 0.05 compared to sham, *p < 0.05 compared to Ant-92a.
M. Fujita et al. / Regenerative Therapy 5 (2016) 9e16 15after LAD coronary artery ligation in all groups except for the sham
surgery group. However, LV dilatation was signiﬁcantly inhibited,
when the GHM sheet impregnated with antagomir-92a but not
antagomir-control was attached on the area at risk of MI.
FS signiﬁcantly decreased 1 h after LAD coronary artery ligation
without an intergroup difference (Fig. 6C). FS remained lower in
these groups 14 days after the LAD coronary artery ligation
compared to the sham surgery group. However, the GHM sheet
impregnated with antagomir-92a signiﬁcantly improved FS
compared to the sheet alone or the sheet impregnated with anta-
gomir-control.
4. Discussion
Since miR-92a expression is increased in the ischemic myocar-
dium immediately after MI, and miR-92a inhibits angiogenesis
in vitro [12], miR-92a has become a target for cardiac regeneration
therapy. The present study demonstrated that attachment of the
GHM sheet impregnated with antagomir-92a on the area at risk ofMI produced robust angiogenesis in the infarct border associated
with cardiac stem cell and cardiomyocyte proliferation. This facil-
itated cardiac regeneration was associated with reduction of scar
formation and improvement of LV function.
We are the ﬁrst to employ the GHM sheet to deliver antagomir-
92a into the heart after MI. The gene therapy system is generally
divided into two categories: viral and non-viral vectors. Although
viral vectors such as retrovirus, adenovirus and adeno-associated
virus are potentially efﬁcient, non-viral vectors have the advan-
tages of less toxicity, less immunogenicity, and easier preparation
[21]. So far several methods to deliver genes with non-viral carriers
have been developed including naked plasmid DNA injection and
complex formation with cationized polymers or cationized lipo-
somes. However, there are several drawbacks with each non-viral
vector, including a low efﬁciency of gene transfection compared
with viral vectors. In contrast, cationized gelatin is a very safe
molecule in human being, and cationized gelatin microspheres
allow controlled release and sustained exposure of RNAs to cells
[22]. Furthermore, the present study suggests that the local
M. Fujita et al. / Regenerative Therapy 5 (2016) 9e1616delivery of antagomir-92a using the GHM sheet to the infarcted
tissue could reduce the dose of the oligonucleotide up to one-tenth
of that administered into systemic circulation as reported by
Bonauer et al. [12]. It may minimize potential side effects such as
unwanted angiogenesis in off-target organs. To prove the advan-
tage of this technique, exact pharmacokinetics and an optimal dose
of antagomir-92a impregnatedwith the GHM sheet attached on the
infarcted heart remains to be investigated.
The present study demonstrated that cardiomyocyte prolifera-
tionwas enhanced by the GHM sheet impregnated with antagomir-
92a. It remains unclear whether proliferation of cardiac stem cells
in the infarcted myocardium using the GHM sheet impregnated
with antagomir-92a solely depends on enhanced angiogenesis. It is
possible that antagomir-92a directly stimulate cardiac stem cells to
migrate toward and proliferate in the infarcted myocardium inde-
pendent of angiogenesis. There have been no previous reports
regarding the effects of miR-92a on cardiac stem cell migration and
proliferation. However, because angiogenesis is indispensable for
cardiomyogenesis [23], antagomir-92a-induced angiogenesis may
provide a suitable niche for cardiac stem cell migration, prolifera-
tion and differentiation into cardiomyocytes. It should also be
noted that cardiac stem cells can differentiate into not only car-
diomyocytes but also endothelial cells and vascular smooth muscle
cells [18e20]. Therefore, it is speculated that antagomir-92a could
promote cardiac regeneration via angiogenesis-dependent and in-
dependent mechanisms.
It also remains unknown whether prevention of scar formation
is simply due to enhanced cardiomyogenesis or to reduced car-
diomyocyte death after MI. The effect of antagomir-92a on car-
diomyocyte protection is controversial. Bonauer et al. [12]
demonstrated that antagomir-92a had no protective effect on
oxidative stress-induced apoptosis in rat neonatal cardiomyocytes,
suggesting that cardiomyogenesis is more important in reducing
scar formation than preventing cardiomyocyte death after MI. On
the other hand, locked nucleic acid-modiﬁed antisense miR-92a
protected cultured cardiomyocytes from hypoxia/reoxygenation-
induced cell death [13]. Besides pro-angiogenic and cytopro-
tective effects, Hinkel et al. [13] also demonstrated an anti-
inﬂammatory effect of the antisense miR-92a. Thus, it is antici-
pated that such pleiotropic effects of antagomir-92a synergistically
contributes to cardiomyogenesis and culminates in robust regen-
eration of the heart after MI.
In conclusion, attachment of the GHM sheet impregnated with
antagomir-92a facilitates cardiac regeneration after MI in rats. The
present study suggests that this technique may be an attractive
surgical regimen either alone or in combination with coronary ar-
tery bypass graft surgery in patients with acute MI.
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